A5081790311- Chronic Lymphocytic Leukemia Research
- CAR-T cell therapy research
- Lymphoma Diagnosis and Treatment
- Phagocytosis and Immune Regulation
- Immunodeficiency and Autoimmune Disorders
- Monoclonal and Polyclonal Antibodies Research
- Glycosylation and Glycoproteins Research
- Multiple Myeloma Research and Treatments
- Acute Lymphoblastic Leukemia research
- Chronic Myeloid Leukemia Treatments
- Glaucoma and retinal disorders
- Peptidase Inhibition and Analysis
- Cancer-related molecular mechanisms research
- Galectins and Cancer Biology
- Protein Degradation and Inhibitors
- Cytokine Signaling Pathways and Interactions
- Mycobacterium research and diagnosis
- Genomic variations and chromosomal abnormalities
- Blood groups and transfusion
- Extracellular vesicles in disease
- Immune Cell Function and Interaction
- Signaling Pathways in Disease
- DNA Repair Mechanisms
- PI3K/AKT/mTOR signaling in cancer
- Chemokine receptors and signaling
Mayo Clinic
2012-2025
WinnMed
2004-2025
Mayo Clinic in Arizona
2008-2022
Mayo Clinic in Florida
2009-2014
University of Minnesota Rochester
2010
Dana-Farber Cancer Institute
2006
Pharmacyclics (United States)
2005
University of Rochester
1990
Retrospective studies suggest cytogenetic abnormalities detected by interphase fluorescent in situ hybridization (FISH) can identify patients with chronic lymphocytic leukemia (CLL) who will experience a more aggressive disease course. Other that may acquire chromosome during the course of their disease. There are minimal prospective data on clinical utility widely used hierarchical FISH prognostic categories newly diagnosed early-stage CLL or frequency clonal evolution as determined...
Summary. Fluorescence in situ hybridization (FISH) was used to detect 6q–, 11q–, +12, 13q–, 17p– and translocations involving 14q32 interphase nuclei from blood and/or bone marrow 113 patients with B‐cell chronic lymphocytic leukaemia (B‐CLL). A total of 87 (77%) had a FISH anomaly: 13q– × 1 most frequent (64%) followed by 2 (28%), +12 (25%), 11q– (15%), (8%) 6q– (0%). results for cells 38 were similar. Purified CD5 + /CD19 studied eight indicate that some not all B have anomalies. We...
Recent reports suggest that the expression of germline (GL) Ig variable region heavy‐chain genes (V H ) is a negative prognostic factor for B‐cell chronic lymphocytic leukaemia (B‐CLL) patients and CLL CD38 may be surrogate marker V gene status. Currently, however, usefulness this controversial. Therefore, our goal was to study ability act as somatic mutation (SM), identify differences in overall survival (OS), progression‐free (PFS) response B‐CLL based on these two markers. We first...
Summary In vitro studies have demonstrated that surface expression of CD49d on chronic lymphocytic leukaemia (CLL) B cells facilitates leukaemic cell–stromal interactions by binding to fibronectin. This interaction reduces both spontaneous and drug‐induced apoptosis. The present study measured flow cytometry in a cohort untreated CLL patients previously accrued prospective observational evaluated the relationship with overall survival (OS). Among 158 tested, percentage expressing ranged from...
Despite the considerable effort to characterize genomic landscape of chronic lymphocytic leukemia (CLL), published data have been almost exclusively derived from patients European Ancestry (EA), with significant underrepresentation minorities, including African (AA). To begin address this gap, we evaluated whether differences exist in genetic and transcriptomic features 157 AA 440 EA individuals diagnosed CLL. We sequenced 59 putative driver genes found an increased frequency high-impact...
Azathioprine and 6-mercaptopurine are antimetabolite thiopurine drugs that play important roles in the treatment of leukemia management conditions requiring immunosuppression, such as inflammatory bowel disease. The biochemical pharmacology these suggests inhibition purine nucleotide formation through 6-thioguanine metabolites is their key molecular mechanism. However, it unclear how suppress immunity. We hypothesized azathioprine produces a selective inhibitory effect on activated but not...
The development of cytopenia in chronic lymphocytic leukaemia (CLL) patients can predict poor prognosis. All CLL seen the Division Hematology at Mayo Clinic Rochester from 1 January 1995 to 31 December 2004 (n = 1750) were evaluated for cytopenia, aetiology and clinical outcome. Cytopenia occurred 423 (24.2%) was attributable 303 (17.3%) cases, with 228 (75%) these having bone marrow (BM) failure 75 (25%) autoimmune disease (AID). Survival onset significantly better AID (median 9.1 years)...
Abstract BACKGROUND Analytically sensitive techniques for measuring minimal residual disease (MRD) in multiple myeloma (MM) currently require invasive and costly bone marrow aspiration. These methods include immunohistochemistry (IHC), flow cytometry, quantitative PCR, next-generation sequencing. An ideal MM MRD test would be a serum-based enough to detect low concentrations of Ig secreted from multifocal lesions. METHODS Patient serum with abundant M-protein before treatment was separated...
Smudge cells are ruptured chronic lymphocytic leukemia (CLL) appearing on the blood smears of CLL patients. Our recent findings suggest that number smudge may have important biologic correlations rather than being only an artifact slide preparation. In this study, we evaluated whether cell percentage a smear predicted survival We calculated percentages (ratio smudged to intact plus lymphocytes) archived from cohort previously untreated patients with predominantly early-stage enrolled onto...
Improved medical care could have altered the clinical presentation and survival of patients with chronic lymphocytic leukemia/small lymphoma (CLL/SLL) complicated by autoimmune disease cytopenia (AID cytopenia). We reviewed characteristics, treatment, outcome AID that was diagnosed in 75 (4.3%) 1750 CLL seen at a single institution over 10 years. When compared historical reported data, our study shows lower rate hemolytic anemia (2.3%), similar rates immune thrombocytopenia (2.0%), pure red...
Multiple myeloma is a disease characterized by clonal expansion of plasma cells that secrete monoclonal immunoglobulin also referred to as an M-protein. In the clinical laboratory, protein electrophoresis (PEL), immunofixation (IFE), and free light chain nephelometry (FLC) are used detect, monitor, quantify Here, we present alternative method based on monitoring clonotypic (i.e., clone-specific) peptide from M-protein heavy variable region using LC–MS/MS. Tryptic digests were performed IgG...
Multiple myeloma (MM) is characterized by the clonal expansion of malignant plasma cells within bone marrow. There a growing literature that tumor release biologically active microvesicles (MVs) modify both local and distant microenvironments. In this study, our goals were to determine if MM MVs, so, begin characterize their biologic activity. Herein we present clear evidence not only do patient human cell lines (HMCLs) but these MVs stimulate growth. Of interest, MM-derived enriched with...
Immunoglobulin light chain (LC) amyloidosis (AL) is caused by deposition of clonal LCs produced an underlying plasma cell neoplasm. The clonotypic LC sequences are unique to each patient, and they cannot be reliably detected either immunoassays or standard proteomic workflows that target the constant regions LCs. We addressed this issue developing a novel sequence template-based workflow detect variable (LCV) region peptides directly from AL amyloid deposits. was implemented in CAP/CLIA...
Patients with chronic lymphocytic leukemia (CLL) usually are treated only for progressive disease. However, the discovery of biologic predictors a high risk disease progression, together development newer, more targeted therapies, could change this paradigm. In phase 2 study, authors tested safety and efficacy early treatment patients high-risk CLL using alemtuzumab rituximab.